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Abstract
Stress is a potent etiological factor in the onset of major depressive disorder and posttraumatic stress
disorder (PTSD). Therefore, significant efforts have been made to identify factors that produce resilience to
the outcomes of a later stressor, in hopes of preventing untoward clinical outcomes. The NMDA receptor
antagonist ketamine has recently emerged as a prophylactic capable of preventing neurochemical and
behavioral outcomes of a future stressor. Despite promising results of preclinical studies performed in male
rats, the effects of proactive ketamine in female rats remains unknown. This is alarming given that
stress-related disorders affect females at nearly twice the rate of males. Here we explore the prophylactic
effects of ketamine on stress-induced anxiety-like behavior and the neural circuit-level processes that
mediate these effects in female rats. Ketamine given one week prior to an uncontrollable stressor (inescap-
able tailshock; IS) reduced typical stress-induced activation of the serotonergic (5-HT) dorsal raphe nucleus
(DRN) and eliminated DRN-dependent juvenile social exploration (JSE) deficits 24 h after the stressor.
Proactive ketamine altered prelimbic cortex (PL) neural ensembles so that a later experience with IS now
activated these cells, which it ordinarily would not. Ketamine acutely activated a PL to DRN (PL-DRN) circuit
and inhibition of this circuit with Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) at
the time of IS one week later prevented stress prophylaxis, suggesting that persistent changes in PL-DRN
circuit activity are responsible, at least in part, for mediating long-term effects associated with ketamine.
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Significance Statement
Stress-related disorders affect females at twice the rate of males, and so identifying factors capable of
producing resilience in females is critically important. Recent efforts to identify neural mechanisms
underlying the prophylactic effects of ketamine on the behavioral and neural impact of a later stressor
have focused solely on male rodents. Here we show that ketamine administered to female rats one
week before an uncontrollable stressor prevents stress-induced anxiety-like behavioral effects. The
mechanisms by which ketamine exerts prophylactic effects were explored, and ketamine was found to
activate an inhibitory prelimbic cortex (PL)-dorsal raphe nucleus (DRN) circuit and that this circuit
activation is required for the stress-buffering effects of ketamine. These data provide a basis for
prophylactic use of ketamine in females.
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Introduction
Stress-related psychiatric disorders, such as depres-
sion and posttraumatic stress disorder (PTSD), affect fe-
males at nearly twice the rate of males (Kessler et al.,
2005; Steiner et al., 2005) and are among the leading
causes of disability worldwide (Kessler et al., 1995;
Mathers et al., 2008). Only one third of patients prescribed
conventional pharmacotherapies achieve full remission,
underscoring the need for more effective therapeutic mo-
dalities. (Gaynes et al., 2009). Recently, it has been shown
that a single subanesthetic dose (0.5 mg/kg, i.v.) of the
nonselective NMDA receptor antagonist ketamine pro-
duces rapid and enduring therapeutic effects in individu-
als with treatment-resistant depression, anxiety, and
PTSD (Berman et al., 2000; Zarate et al., 2006; Glue et al.,
2017; Price et al., 2009; Feder et al., 2014). Accordingly, a
growing body of research has been dedicated to identi-
fying the underlying neurobiological mechanisms by
which ketamine produces its effects.
Because of its clinical effectiveness, laboratory work
has focused on two paradigms. In one, a single subanes-
thetic dose (10 mg/kg, i.p.) of ketamine is delivered at
various time points before behavioral tests that are
thought to reflect depressive or anxiety-related behavior.
For example, ketamine delivered minutes to hours before
behavioral testing prevents typical behavioral changes
measured during the forced swim test (Garcia et al.,
2008), tail suspension test (da Silva et al., 2010), novelty
suppressed feeding test (NSF; Fuchikami et al., 2015) and
the open-field test (Thelen et al., 2016). In the second,
ketamine is given after exposure to a stressor to deter-
mine whether it would reverse stress effects on behavior.
Ketamine delivered shortly after (0–24 h) exposure to a
chronic unpredictable stressor reverses the effects of the
stressor on NSF and sucrose preference (Li et al., 2011).
Surprisingly, nearly all of the preclinical studies designed
to identify the mechanistic actions of ketamine have fo-
cused on male rats. Indeed, a small number of studies
have demonstrated differential sensitivity and responsivity
of females and males to the direct and restorative effects
of ketamine (Carrier and Kabbaj, 2013; Frnasceschelli
et al., 2015; Zanos et al., 2016).
There has been a great deal of recent interest in factors
that can lead to resilience in the face of adversity (for
review, see Baratta et al., 2013), and interestingly, 3 re-
cent reports indicate that single dose of ketamine can
blunt the impact of stressors occurring as much as two
weeks later (Amat et al., 2016; Brachman et al., 2016;
McGowan et al., 2017). Unfortunately, none of these re-
ports employed female subjects. Thus, we chose to ex-
plore the proactive effects of ketamine in female rats, as
well as the underlying neural circuit-level processes that
mediate such effects. We sought to determine whether
ketamine delivered one week before an uncontrollable
stressor (inescapable tailshock; IS) is sufficient to prevent
anxiety-like behavior measured during juvenile social ex-
ploration (JSE) 24 h later, in a manner similar to that
observed in male rats (Amat et al., 2016). IS-induced
behavioral changes are mediated in part by activation of
serotonergic (5-HT) neurons within the dorsal raphe nu-
cleus (DRN; Maier and Watkins, 2005). Specifically, IS
activates 5-HT neurons in the mid to caudal DRN (Grahn
et al., 1999) leading to 5-HT release in projection regions
that are proximal mediators of stress-induced behavioral
changes, such as the basolateral amygdala (BLA; Amat
et al., 1998; Christianson et al., 2010; Dolzani et al., 2016).
Indeed, blockade of 5-HT2C receptors in the BLA elimi-
nates the reduction in JSE produced by prior IS (Chris-
tianson et al., 2010). Therefore, we examined the effect of
ketamine on IS-induced Fos activation in DRN 5-HT neu-
rons to determine whether ketamine mitigates IS-induced
DRN activation (Amat et al., 2016). Plastic changes in
the prelimbic region (PL) of the medial prefrontal cortex
(mPFC), a potent regulator of DRN activity (for review, see
Maier and Watkins, 2010), are critical for the stress-
buffering effects of ketamine (Li et al., 2010; Lepack et al.,
2016; for review, see Duman and Krystal, 2016). Thus, we
explored whether ketamine alters PL neural ensembles so
that later IS now activates the same ensembles. Finally,
we examined whether ketamine directly activates the PL-
DRN pathway, and if so, whether PL-DRN pathway acti-
vation is critical for the protective effects of ketamine at
the time of later IS.
Materials and Methods
Experimental design
The first set of experiments examined whether a single
dose of ketamine would mitigate the behavioral and neu-
rochemical effects of IS. Therefore, low-dose ketamine
(10 mg/kg, i.p.), which is protective against stress out-
comes in male rats (Li et al., 2010; Amat et al., 2016), was
administered to female rats one week (7 d) before IS or HC
treatment. Separate groups of rats received high-dose
ketamine (40 mg/kg, i.p.), which is not implicated in stress
resistance (Chowdhury et al., 2017), or saline. Anxiety-like
behavior was assessed during a JSE test 24 h after the
stressor. Thus, the experiment was a 2 (stress)  3 (drug)
factorial design. Two-way ANOVA was used for statistical
analysis. Previous work performed using similar parame-
ters (Dolzani et al., 2016) demonstrates that n  9–12/
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group are sufficient to achieve statistical significance
between groups. Three rats were considered statistical
outliers (2.5 SDs from the mean) and were excluded
from the statistical analysis. The one-week time point was
selected to dissociate the long-term stress-buffering ef-
fects of the ketamine from potential acute effects, which
are not the focus of the present work. Additionally, previ-
ous work from our laboratory demonstrates that ketamine
delivered one-week before IS in male rats protects against
the typical effects of the stressor (Amat et al., 2016). DRN
5-HT activation was assessed in a separate group of rats
using double label immunohistochemistry (IHC) to deter-
mine whether ketamine reduces overall stress-induced
Fos expression within the DRN, and whether this reduc-
tion occurs in 5-HT neurons within the DRN. Fos and 5-HT
expression were examined in the rostral, middle, and
caudal DRN. Thus, the experiment was a 2 (stress)  2
(drug) factorial design. Two-way ANOVA was used to
separately analyze total 5-HT cells, total Fos, and the
percentage of 5-HT cells that also were also Fos
between all possible groups. Previous work from our
laboratory (Dolzani et al., 2016) demonstrates that n 
10–12/group (two brain slices per rat) are sufficient for
detecting statistical differences in immunohistochemical
labeling between groups. Four rats were considered sta-
tistical outliers (2.5 SD from group mean for cell counts
or insufficient staining for detection) and were removed
from the analysis.
The major source of inhibitory control over DRN 5-HT
neurons derives from descending PL glutamatergic pyra-
midal neurons that synapse preferentially on GABA in-
terneurons in the DRN (Jankowski and Sesack, 2004).
Interestingly, behavioral control blunts the impact of a
stressor by activating this inhibitory pathway (Amat et al.,
2005; Baratta et al., 2009). Moreover, the experience of
control also has a prophylactic effect in that it blocks the
behavioral effects of later uncontrollable stressors such
as IS (Amat et al., 2006) and social defeat (Amat et al.,
2010). After a prior experience with control, an uncontrol-
lable stressor now does not activate DRN 5-HT neurons
(Baratta et al., 2009). This occurs because the experience
of control alters the PL-DRN pathway so that it is now
activated by even uncontrollable stressors such as IS
(Baratta et al., 2009). Thus, the second set of experiments
sought to determine whether ketamine might engage the
same mechanisms as behavioral control and alter PL
neurons so that later IS now activates the PL. We used the
recently developed immediate early gene (IEG) platform
Robust Activity Marker (RAM) to interrogate neural activity
at two time points: the time of initial ketamine injection
(time 1), and the time of later IS (time 2). RAM provides a
means for labeling neuronal ensembles activated by a
particular temporally defined experience or event (for de-
tailed explanation, see Sørensen et al., 2016). When com-
bined with a subsequent IEG labeling technique, such as
IHC, RAM allows for interrogation of neuronal activity at
multiple time points. RAM utilizes a synthetic activity-
dependent promoter (pRAM), which is driven by neuronal
specific FOS and NPAS4 activity. pRAM activity drives
expression of a tetracycline transactivator domain (tTA),
which binds to a tetracycline-response element (TRE) and
drives expression of the effector gene, mKate2. Temporal
control over RAM is achieved using a modified Tet-Off
system. Binding of the tTA to the TRE is inhibited in the
presence of DOX (DOX). In the absence of DOX (DOX-),
effector gene transcription is enabled. Therefore, we used
RAM to determine whether ketamine activates PL neu-
rons at the time of injection (time 1) and whether a later
experience with IS (time 2) now activates the same, or
different, neuronal ensembles as did prior ketamine. Im-
portantly, low- and high-dose ketamine were adminis-
tered to separate groups of rats to determine whether
IS-induced activation of neural ensembles previously ac-
tivated by ketamine is specific to a dose of ketamine that
protects against behavioral outcomes of stress. Thus, the
experiment was a 2 (stress)  3 (drug) factorial design.
Two-way ANOVA was used to separately analyze total
RAM, total Fos, and the percentage of RAM that were
also Fos between all groups. Previous work by Sø-
rensen et al. (2016) demonstrates that n  6–8/group
(two brain slices per rat) are sufficient to detect statistical
differences between groups in experiments performed
using similar parameters. Five rats were considered out-
liers (2.5 SDs from mean for cell counts or failure to
detect expression of the injection control (eYFP).
The third experiment examined whether ketamine acti-
vates the PL-DRN circuit. Red fluorescent retrogradely
transported microspheres (hereafter referred to as ret-
robeads; RBs) were injected into the DRN two weeks
before rats receiving a single injection of ketamine. Two
hours later, rats were killed and Fos expression was as-
sessed in the PL and PL-DRN pathway. An independent
samples t test was used to examine differences in total
RB-positive (RB) cells, total Fos cells, and the per-
centage of RB cells that were also Fos; n 6–8/group
(two brain slices per rat) are sufficient to detect statistical
differences between groups. Two rats were considered
outliers (2.5 SD from mean for cell counts) and excluded
from analysis. Additionally, 4 rats were excluded from
analysis due to inaccurate DRN RB injections.
The final experiment examined whether the PL-DRN
circuit is necessary for the protective effects of ketamine.
This requires selective inhibition of PL neurons that proj-
ect to the DRN. Addressing this required the use of a dual
viral intersectional genetic strategy to target Designer
Receptors Exclusively Activated by Designer Drugs
(DREADDs) to DRN-projecting PL neurons. A retrogradely
transported AAV vector encoding Cre recombinase was
delivered into the DRN and double-floxed AAV vector
encoding the inhibitory DREADD receptor, (hM4Di) or
mCherry (control virus), was delivered into the PL. This
approach enables selective inhibition of neurons follow-
ing systemic injection of clozapine-N-oxide (CNO; Arm-
bruster et al., 2007; Ferguson et al., 2011; Rogan and
Roth, 2011), as verified by reduced expression of c-Fos
(Ferguson et al., 2011; Soumier and Sibille, 2014). to
validate hM4Di-mediated inhibition of the PL-DRN path-
way, we used an independent samples t test to assess
total PL-DRN hM4Di/mCherry expression, total Fos,
and the percentage of hM4Di/mCherry expressing cells
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that were also Fos. In a separate cohort, rats expressing
hM4Di or mCherry in the PL-DRN pathway were injected
with ketamine or saline, and one week later they received
CNO injection 30 min before IS. Anxiety-like behavior was
assessed 24 h later during JSE. Therefore, the experiment
was a 2 (virus)  2 (stress)  2 (drug) factorial design.
Three-way ANOVA was used for statistical analysis. Pre-
vious work using similar parameters (Dolzani et al., 2016)
demonstrates that n  10–12/group are sufficient to de-
tect statistical significance. Three rats were considered
statistical outliers (2.5 SD from mean), and were re-
moved from the statistical analysis. Additionally, two rats
were excluded due to stress-related paw injuries, and six
rats were excluded due to inaccurate or failed viral injec-
tions, as determined after completion of the experiment.
Data analysis for all one-way ANOVA, two-way ANOVA,
and t tests was performed using Prism software (Graph-
Pad). Three-way ANOVA was performed using Statview
(SPSS). All experiments were performed using a between-
subjects design and the effect of treatment was analyzed
with unpaired t test (drug), one-way (stress), two-way
(stress and drug), or three-way (stress and drug and virus)
ANOVA. Main effects and interactions were considered
statistically significant if p 0.05. When appropriate, post
hoc analyses and planned comparisons were performed
using Tukey’s post hoc method. Values in graphs are
represented as mean  SEM.
Rats
Adult female Sprague Dawley rats (250–300 g; Envigo)
were pair housed on a 12/12 h light/dark cycle (lights on
at 7 A.M. and off at 7 P.M.). Rats were housed with free
access to food and water and were allowed to acclimate
to colony conditions for 7 d before surgical or experimen-
tal procedures. All stereotactic surgeries were performed
under 2.5% isoflurane (Piramal Critical Care) anesthesia.
Rats received preoperative analgesic (meloxicam, 0.5 mg/
kg, s.c.; Vetmedica) and antibiotic (Combi-Pen-48, 0.25
ml/kg, s.c.; Bimeda) before surgical procedures. Rats
were given two weeks to recover from surgery before
experimentation. All experiments were performed be-
tween 9 A.M. and 5 P.M. All animal procedures were
approved by the Institutional Animal Care and Use Com-
mittee at the University of Colorado Boulder and con-
formed to National Institutes of Health Guidelines on the
Care and Use of Laboratory Animals.
Drug administration
In all experiments, ketamine (Ketalar, Pfizer) was ad-
ministered at 10 or 40 mg/kg intraperitoneally. This dose
was based on parameters previously described (Li et al.,
2010; Amat et al., 2016; Chowdhury et al., 2017).
Stress procedure
IS was delivered as previously described (Amat et al.,
2005; Christianson et al., 2013). Briefly, rats were placed
in a PlexiGlas restraint tube (8  18 cm, diameter 
length). The rat’s tail was secured to a Plexiglas postpro-
truding from the rear portion of the box using medical tape
and copper electrodes were placed around the tail. Shock
was delivered to the rat’s tail with increasing intensity as
the shock session progressed (33 trials at 1.0 mA, 33 trials
at 1.3 mA, and 34 trials at 1.6 mA). Shock was delivered
with an average intertrial interval (ITI) of 60 s. Rats were
removed from the PlexiGlas boxes and placed in their
home cage immediately after the last tailshock. Non-
shocked homecage control (HC) rats were left undis-
turbed in the colony.
JSE
JSE testing was conducted 24 h after IS or HC, as
previously described (Amat et al., 2016). Any rats showing
signs of injury (including injured hindpaws, forepaws, or
toenails) after the stress session were excluded. Precau-
tions are taken to minimize the frequency of these occur-
rences, but nonetheless injuries did occur in a small
subset of subjects. Each experimental subject was singly
assigned to an empty plastic cage with shaved wood
bedding and a wire lid. Experimental subjects remained in
the test cage for 45 min to 1 h before introducing a
juvenile (28  2 d old) female conspecific. An observer,
blind to treatment, recorded exploratory behavior (allog-
rooming, licking, sniffing, and pinning) initiated by the
experimental subject during a 3-min test. JSE test scores
were reported as a total time (s) of social exploration
during the 3-min test.
Fluorescent IHC
Staining for Fos was performed using a general immu-
nofluorescence protocol. Following a series of washes in
0.01 M PBS containing 0.5% Triton X-100, slices were
incubated overnight in a PBS blocking solution containing
0.5% Triton X-100 (PBST) and 2.5% bovine serum albu-
min (BSA) at 4°C. Then, slices were washed in PBST and
incubated for 24 h at room temperature (RT) in rabbit
polyclonal primary antibody (1:1000; Santa Cruz Biotech-
nology) in blocking solution. After a series of PBS washes,
slices were incubated for 2 h at RT in Alexa Fluor 405 goat
antirabbit secondary antibody (1:250; Life Technologies).
After a series of PBS washes, tissue was floated onto
slide glass and coverslipped with Vecta Shield (Vector
Labs).
Image analysis for fluorescent IHC experiments
Brain sections were observed using a Nikon N-SIM
structured illumination super-resolution laser scanning
confocal microscope (Nikon). Images were captured us-
ing NIS Elements (Nikon) and analyzed using FIJI (Im-
ageJ). All digital images were captured using a 20
objective. For imaging and quantification of PL (taken
between AP: 2.5 mm to 3.0 mm relative to bregma)
boundaries were based on those previously described
(Baratta et al., 2009) with consultation to the brain atlas
(Paxinos and Watson, 2011). In the PL-DRN retrograde
tracing experiment, RB cell bodies in the PL were ob-
served using a 546-nm laser line and were pseudocolored
red. Fos nuclei were observed using a 405-nm laser line
and were pseudocolored blue. RB and Fos cells in the
PL were quantified and recorded separately. Colocaliza-
tion of RB and Fos was reported when a red/magenta cell
body representing the intermixture of the two fluoro-
phores was observed and verified to be overlapping RB
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and Fos cells. In the PL RAM experiment, eYFP-labeled
neurons (site of viral injection) were observed using a
488-nm laser line and were pseudocolored green. eYFP
expression was confirmed in all subjects included in sta-
tistical analysis. Following confirmation of accurate viral
injection, RAM-labeled nuclei were observed using a
546-nm laser line and were pseudocolored red. Fos
nuclei were observed using a 405-nm laser line and were
pseudocolored blue. RAM and Fos cells in the PL
were quantified and recorded separately. Colocalization
of RAM and Fos was reported when a magenta nucleus
representing the intermixture of the two fluorophores was
observed and verified to be overlapping RAM and Fos. In
the DREADD-mediated PL-DRN pathway silencing exper-
iment, DREADD or mCherry positive cells were observed
using a 546-nm laser line and were pseudocolored red.
Fos cells were observed using a 405-nm laser line and
were pseudocolored green. DREADD and Fos cells in
the PL were quantified and recorded separately. Colocal-
ization of DREADD and Fos was reported when a yellow
nucleus representing the intermixture of the two fluoro-
phores was observed and verified to be overlapping DRE-
ADD and Fos. For each subject, two separate counts were
taken from PL tissue spanning AP: 2.5 mm to 3.0 mm.
The two counts for each subregion were averaged and
used for statistical analysis.
Effect of ketamine on later JSE
Rats randomly assigned to drug and stress treatment
received a single systemic injection of ketamine (10 or 40
mg/kg, i.p.) or vehicle one week before IS or HC. Twenty-
four hours after the completion of IS or HC, rats received
JSE testing.
Effect of ketamine on stress-induced Fos activation
in the DRN
Tissue preparation
Rats injected with ketamine 1 w before IS or HC were
deeply anesthetized with sodium pentobarbital (65 mg/kg)
2 h after the last tailshock or at the same time for rats
assigned to HC. Rats were transcardially perfused with
100-ml ice-cold 0.9% saline, immediately followed by
250-ml 4% paraformaldehyde in 0.1 M phosphate buffer
(PB; pH 7.4). Brains were postfixed overnight in the
same fixative and transferred to a 30% sucrose solution in
0.1 M PB then stored at 4°C until sectioning. Coronal
brain sections containing DRN were obtained at 35 m.
DRN tissue used for IHC was placed directly into a 24-well
plate.
IHC for Fos and 5-HT
Staining for Fos and 5-HT was conducted as previously
described (Grahn et al., 1999). Staining for Fos was con-
ducted using the avidin-biotin-horseradish peroxidase
(ABC) method. Following a series of washes in 0.1 M PBS,
sections were incubated in a 0.9% hydrogen peroxide
solution to quench endogenous peroxidases. Then, sec-
tions were incubated for 24 h at RT with Fos primary
antibody (1:15,000; Santa Cruz Biotechnology) in a block-
ing solution containing 2% normal goat serum (NGS),
0.5% Triton X-100 and 0.1% sodium azide. Following the
primary antibody incubation, sections were incubated for
2 h at RT in biotinylated goat anti-rabbit secondary anti-
body (1:200; Jackson ImmunoResearch) in blocking so-
lution. After a series of PBS washes, slices were then
incubated in ABC for 1 h at RT. Next, sections were
washed in 0.1 m PB and then exposed to a solution
containing 3,3-diaminobenzidine (DAB), cobalt chloride,
nickel ammonium sulfate, ammonium chloride and glu-
cose oxidase in PB. The peroxidase reaction was initiated
by the addition of a glucose solution that reacted with the
tissue for 7–10 min. The reaction was terminated by
washing sections with PBS. Tissue was floated onto slide
glass and cover slipped for later analysis. 5-HT staining
was conducted using the peroxidase anti-peroxidase
(PAP) method. Following a series of washes in PBS, ex-
cess background 5-HT staining was prevented by incu-
bating sections in blocking solution for 0.5 h. Next, tissue
was incubated in blocking solution of 5-HT antibody (rab-
bit polyclonal 1:10,000; Jackson ImmunoResearch) for 48
h at RT. Goat anti-rabbit secondary antibody (1:200;
Jackson ImmunoResearch) was applied to the tissue for 2
h after a series of PBS washes. This step was followed by
another series of PBS washes and incubation with PAP
antibody (1:200; Jackson ImmunoResearch) for 2 h. Fol-
lowing a series of washes in PBS, tissue was incubated in
a solution containing DAB and glucose oxidase. The per-
oxidase reaction was initiated by addition of glucose and
continued for 15 min. After a final series of PBS washes,
tissue was mounted on slides and allowed to dry over-
night. Slides were coverslipped with Permount.
Image analysis
Brain sections were observed using a bright field mi-
croscope (Olympus BX-61, Olympus America) and ana-
lyzed using cellSens software (Olympus America). All
digital images were captured using a 20 objective. Im-
ages of DRN were taken using parameters similar to those
previously described (Grahn et al., 1999). Sections corre-
sponding to an AP coordinate of -1.36, -1.00, and -0.70
mm relative to interaural zero were taken for rostral, mid-
dle, and caudal DRN, respectively. Fos-positive nuclei in
each subregion of the DRN were observed as dark brown
or black round/ovoid spots. 5-HT-stained cell bodies
were observed as light brown particles with and without
unstained nuclei. Colocalization of Fos and 5-HT was
observed as a light brown cell body with a black stained
nucleus. For each subject, two separate counts were
taken from different slices within each subregion of the
DRN. The two counts for each subregion were averaged
and used for statistical analysis.
Effect of ketamine on activation of the PL-DRN
pathway
Microinjection of retrograde tracer
A small window (1 1 mm) was drilled into the skull and
red fluorescent RBs (Lumafluor) were microinjected into
the DRN (AP: -8.0 mm relative to bregma, DV: -6.7 mm
from skull surface, ML: 0.0 mm relative to midline) using
a 10-l Hamilton syringe and a 31-gauge metal needle
with a 45° beveled tip. The total injection volume (0.3 l)
and flow rate (0.1 l/min) was controlled with a microin-
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jection pump (UMP3-1; World Precision Instruments).
This injection volume was chosen based on pilot experi-
ments in which robust RB expression was observed
within the PL two weeks after 0.3-l injection, while main-
taining localized injections. Following injection, the needle
was left in place for an additional 10 min to allow for RB
diffusion, after which the needle was withdrawn. The
small scalp incision was closed using Vetbond (3M). Pre-
operative antibiotic (Combi-Pen-48, 0.25 ml/kg, s.c.) and
a postoperative analgesic (meloxicam, 2 mg/kg, s.c.) was
administered to all rats. Two weeks after RB microinjec-
tion, rats received a systemic injection of ketamine or
saline and were killed 2 h later. RB microinjections were
considered successful if expression was visibly confined
to DRN in coronal sections of brain obtained after com-
pletion of the experiment. Only rats with accurate RB
injections were used for statistical analysis.
Tissue preparation
Rats were deeply anesthetized with sodium pentobar-
bital (65 mg/kg) at 2 h following the ketamine or saline
injection. Rats were transcardially perfused with 100-ml
ice-cold 0.9% saline, immediately followed by 250-ml 4%
paraformaldehyde in 0.1 M PB (pH 7.4). Brains were
postfixed overnight in the same fixative and transferred to
a 30% sucrose solution in 0.1 M PB then stored at 4°C
until sectioning. Coronal brain sections containing PL were
obtained at 35 m. PL tissue used for IHC was placed
directly into a 24-well plate. DRN tissue was mounted onto
glass slides and coverslippedwith VectaShield (Vector Labs)
mounting medium.
Effect of ketamine on PL neural ensembles at the
time of initial injection and at the time of later stress
Virus
Adeno-associated virus (AAV) vectors were used to
target the RAM-NLS-mKate2 (RAM) fusion transgene to
neurons. RAM cassettes were packaged in AAV vectors
serotyped with AAV1 coat proteins (titers: 2.18  1013
genome copies/ml) by Virovek. hSYN-eYFP (eYFP) cas-
settes packaged in AAV vectors serotyped with AAV1
coat proteins were (titers: 3.86  1012 genome copies/ml)
by University of Pennsylvania. Before injection, RAM was
mixed with eYFP (8.5-l RAM/1.5-l eYFP). eYFP is ex-
pressed in the absence of neuronal activation, and serves
as method of determining injection accuracy following
completion of the experiment. This ensures that in the
absence of RAM expression, injection verification can be
achieved.
Viral vector delivery
Rats were placed on doxycycline chow (DOX; 200 mg/
kg, BioServ) 24 h before surgery as previously described
(Sørensen et al., 2016). On the day of surgery, rats were
anesthetized and a single unilateral injection of RAM was
directed to the PL (AP: 2.5 relative to bregma, DV: -2.0
relative to pial surface, ML: 1.0 mm) using injection
parameters similar to those described above. 1000 nl of
RAM was delivered at a rate of 100 nl/min. Following
completion, the injection needle was left in place for an
additional 10 min to allow for diffusion of virus, after which
the needle was withdrawn. Postoperative care was per-
formed as described above.
Labeling of neuronal ensembles at the time of ketamine
injection and later stress
Following injection of RAM, rats remained on DOX
chow (200 mg/kg) for 96 h. This period of time is sufficient
to prevent basal induction of RAM in the absence of a
salient event, such as drug injection. DOX chow was
withdrawn and replaced with standard lab chow 96 h
later. Removing DOX chow 96 h prevents RAM expres-
sion due to circulating DOX-mediated transgene suppres-
sion (data not shown). Rats remained undisturbed in the
colony for 96 h following the withdrawal of DOX. Following
the 96 h DOX- interval, rats randomly assigned to drug
and stress treatment were injected with either low-dose
ketamine (10 mg/kg, i.p.), high-dose ketamine (40 mg/kg,
i.p.), or saline. Twenty-four hours later, rats were placed
back on DOX chow (1000 mg/kg). This time interval allows
for robust expression of RAM, while minimizing nonspe-
cific RAM expression. 48 h later, rats received IS or HC
and were perfused 2 h later.
Tissue preparation
Rats were deeply anesthetized and perfused as de-
scribed above. Coronal brain sections containing PL were
obtained at 35 m. PL tissue used for IHC was placed
directly into a 24-well plate. Fluorescent IHC was per-
formed as described above.
Effect of PL-DRN inhibition on the stress buffering
effects of ketamine
Virus
AAV2-retro-eSyn-eGF-T2A-iCre-WPRE (Cre) cassettes
were packaged in AAV vectors serotyped with AAV coat
proteins (titers: genome copies/ml) by Vector Biolabs.
AAV8-hSyn-DIO-hM4Di(Gi)-mCherry (hM4Di) cassettes
were packaged in AAV vectors serotyped with AAV8 coat
proteins (titers: 4.3  1012 genome copies/ml) by Add-
gene. AAV-hSyn-DIO-mCherry (mCherry) cassettes were
packaged in AAV vectors serotyped with AAV5 coat pro-
teins were (titers: 2.1 1013 genome copies/ml) by Add-
gene.
Viral vector delivery
A small window (1 1 mm) was drilled into the skull and
Cre was microinjected into the DRN (AP: -8.0 mm relative
to bregma, DV: -6.7 mm from skull surface, ML: 0.0 mm
relative to midline) using a 10-l Hamilton syringe and a
31-gauge metal needle with a 45° beveled tip. The total
injection volume (1 l) and flow rate (0.1 l/min) was
controlled with a microinjection pump (UMP3-1; World
Precision Instruments). Following injection, the needle
was left in place for an additional 10 min to allow for virus
diffusion, after which the needle was withdrawn. The
small scalp incision was closed using Vetbond (3M). Pre-
operative antibiotic (Combi-Pen-48, 0.25 ml/kg, s.c.) and
a postoperative analgesic (meloxicam, 2 mg/kg, s.c.) was
administered to all rats. Five days later using identical
surgical procedures, hM4Di or mCherry was microin-
jected into the PL (AP: 2.5 mm relative to bregma, DV:
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-2.0 mm from pial surface, ML: 0.5 mm relative to
midline).
hM4Di validation
To determine whether CNO delivery is sufficient to
prevent activation of PL-DRN neurons, rats targeted with
hM4Di to the PL-DRN pathway received a single injection
of CNO (3.0 mg/kg, i.p.) or vehicle 30 min before receiving
a single injection of ketamine (10 mg/kg, i.p.). Rats were
perfused 90 min later. Coronal brain sections containing
PL were obtained at 35 m. PL tissue used for IHC was
placed directly into a 24-well plate. Fluorescent IHC was
performed and Fos expression was examined in the PL-
DRN pathway. Only rats with accurate bilateral expression
of hM4Di were included in the statistical analysis.
Estrous cycle determination
Vaginal lavage was performed before stress treat-
ment. A blunt-tipped eyedropper filled with a small
amount of 0.9% sterile saline was inserted into the
vagina. Fluid was quickly expelled two to three times to
gently wash off and collect vaginal cells (0.25 ml). A
drop was placed onto a glass slide and immediately
examined with a 40 objective lens. Characteristic
changes in the cytological appearance of the samples
were used to identify the cycle stage: diestrus I/II (pres-
ence of nucleated cells and leucocytes), proestrus
(presence of nucleated cells), and estrus (presence of
anucleated squamous cells).
PL-DRN silencing
Rats targeted with hM4Di or mCherry to the PL-DRN
pathway were randomly assigned to drug and stress
treatment. Rats received a single systemic injection of
ketamine or vehicle one-week before IS or HC. Rats
received a single injection of CNO (3.0 mg/kg, i.p.) 30 min
before IS or HC treatment. Twenty-four hours after the
completion of IS or HC, behavior was assessed during
JSE. Following completion of behavioral testing, rats
were deeply anesthetized and perfused using saline
and 4% paraformaldehyde. Coronal sections contain-
ing PL and DRN were mounted directly onto slides and
accurate viral expression in the PL-DRN pathway was
confirmed. Only rats with accurate bilateral expression
of hM4Di or mCherry were included in the statistical
analysis.
Statistics
Data analysis was performed with Prism software
(GraphPad). The effect of treatment was analyzed with un-
paired t test (drug), or one-way (stress), two-way (stress and
drug), or three-way (stress and drug and virus) ANOVA. Main
effects and interactions were considered statistically signif-
icant if p  0.05. When appropriate, post hoc analyses and
planned comparisons were performed using Tukey’s post
hoc method. Values in graphs are represented as mean 
SEM.The results of all statistical analyses are listed inStatistics.
Results
Effect of systemic ketamine on JSE and DRN 5-HT
activation
Behavior
Rats received either low-dose ketamine (10 mg/kg, i.p.),
high-dose ketamine (40 mg/kg, i.p.) or saline (i.p.) 7 d before
IS or HC (n  9–10/group). Anxiety-like behavior was as-
sessed during JSE 24 h later. Figure 1 shows the total time
spent interacting during the 3-min JSE test. Prior low- or
high-dose ketamine delivered to HC, rats had no effect on
JSE, relative to saline injected HC controls. JSE was signif-
icantly reduced in rats previously injected with saline or
high-dose ketamine that received IS. Importantly, low-dose
ketamine delivered one week prior completely blocked the
effect of IS on JSE. Two-way ANOVA revealed significant
main effects of stress (F(1,52)  21.13, p  0.0001), drug
(F(2,52) 12.62, p 0.0001), and a stress by drug interaction
(F(2,52)  3.97, p  0.025). Tukey’s post hoc method re-
vealed that rats administered saline or high-dose ketamine
before IS were indistinguishable from each other but differed
from all other groups (p 0.05). Rats administered low-dose
ketamine and IS differed significantly from rats that received
saline and IS or high-dose ketamine and IS, while IS rats
previously administered low-dose ketamine were indistin-
guishable from HC rats that previously received saline, low-
dose ketamine, or high-dose ketamine. Social exploration
was significantly reduced in rats administered saline and IS
(p  0.0009) or high-dose ketamine and IS (p  0.03)
compared to their respective home cage group.
DRN 5-HT activation
To determine whether ketamine prevents typical IS-
induced activation of the DRN, we assessed Fos immu-
noreactivity (Fos), 5-HT immunoreactivity (5-HT), and
Figure 1. Low-dose ketamine protects female rats against later stress-induced JSE deficits. A, Rats received low (10 mg/kg, i.p.) or
high (40 mg/kg, i.p.) dose ketamine one week before stress or HC treatment. JSE was measured 24 h after stress or HC treatment.
Tukey’s post hoc method: p  0.05, p  0.001. Bars represent group mean  SEM.
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the percentage of 5-HT cells also expressing Fos (%5-
HT cells expressing Fos) in the rostral, middle, and
caudal DRN of rats injected one week prior with low-dose
ketamine or vehicle (Fig. 2). We focused specifically on
these three subregions of the DRN because prior work
demonstrates that, in male rats, IS activates the middle
and caudal DRN (Grahn et al., 1999). Similarly, the 2-h
time point was chosen based on previous experiments
demonstrating stress-induced Fos in the DRN (Grahn
et al., 1999). Figure 2A shows a representative photomi-
crograph denoting a 5-HT cell, a Fos cell, and a
5-HT cell also expressing Fos. Two-way ANOVA was
used to examine whether the total number of 5-HT cells
varied between groups within the rostral, middle, or cau-
dal DRN. No differences in the total number of 5-HT
cells were observed (p  0.05) between stress groups for
the rostral, middle, or caudal subregions of the DRN (data
not shown). Fos cells were examined within each DRN
subregion for the different treatment groups (Fig. 2B, left).
Within the rostral DRN, a two-way ANOVA revealed a
main effect of drug (F(1,38)  4.29, p  0.046) and a main
effect of stress (F(1,38)  15.22, p  0.0004). Tukey’s post
hoc analysis revealed that IS rats show an increase in
Fos, relative to rats that received HC (p  0.05). Fos
was significantly reduced in rats previously administered
ketamine that received IS compared to rats administered
saline before IS (p  0.05). Within the middle DRN, stress
increased Fos; however, this effect was partially pre-
vented by prior ketamine. These observations were con-
firmed by two-way ANOVA, which revealed main effects
of stress (F(1,39) 14.94, p 0.0004), drug (F(1,39) 4.539,
p  0.04), and a stress  drug interaction (F(1,39)  4.303,
p  0.045). Post hoc analysis demonstrated that Fos
was significantly increased in IS rats, relative to HC rats
(p  0.01). Ketamine delivered before IS reduced Fos
relative to IS rats that received saline (p  0.05). The
number of Fos cells in the caudal DRN was greater after
IS than HC. This was confirmed by two-way ANOVA,
which revealed a main effects of stress (F(1,36)  9.446,
p  0.004). Not surprisingly, IS produced a robust in-
crease in the number of 5-HT cells (5-HT Fos) in the
rostral, middle and caudal DRN (Fig. 2B, right). Within the
rostral DRN, a two-way ANOVA revealed main effects of
stress (F(1,38)  20, p  0.0001) and drug (F(1,38)  4.255,
p  0.046). Compared to HC rats previously administered
saline, IS rats that received saline showed enhanced
5-HT cells also expressing Fos (p  0.05). The number
of 5-HT cells also expressing Fos was reduced in IS rats
that previously received ketamine compared to IS rats
that received saline (p  0.05). Within the middle DRN,
two-way ANOVA yielded main effects of stress (F(1,39) 
26.58, p  0.0001), drug (F(1,39)  5.048, p  0.03), and a
stress  drug interaction (F(1,39)  5.037, p  0.03). As
observed in the rostral DRN, rats previously administered
saline or ketamine that received IS showed an enhance-
ment in the number of 5-HT cells also expressing Fos,
compared to rats that received saline or ketamine and HC
(p  0.0001). Prior ketamine reduced the IS-induced en-
hancement of 5-HT cells also expressing Fos, relative to
saline treated rats that received IS (p  0.05). Finally,
within the caudal DRN, two-way ANOVA revealed a main
effect of stress (F(1,36) 23.01, p 0.0001). Saline treated
rats that received IS showed enhanced 5-HT cells also
expressing Fos compared to saline and ketamine treated
HC rats (p  0.001). In sum, IS activated DRN 5-HT
neurons, and this activation was substantially blunted by
ketamine administered 7 d earlier.
Effect of ketamine on the activity of PL at the time of
stress
Previous work demonstrates a role for deep layer (Layer
V/VI) PL neurons in the stress-buffering effects of both
ketamine and behavioral control (Amat et al., 2005, 2016;
Varela et al., 2012). Therefore, we sought to determine
whether prior ketamine might induce activation of neural
ensembles within the PL, so that a later experience with IS
now would activate the PL, in a manner consistent with
behavioral control in males (Baratta et al., 2009). Such
findings would suggest that the protective effects of ket-
amine are mediated, at least in part, by enduring changes
in a neural node commonly studied with regard to inhib-
itory control over the DRN (Amat et al., 2005; Baratta
et al., 2009). Figure 3A shows a schematic diagram of the
experimental timeline. First, we sought to determine
whether a single injection of ketamine (Fig. 3B) would
induce RAM (RAM) expression, indicative of PL activa-
tion (Fig. 3C,D). To optimize activity-dependent RAM
expression, we assessed two different time intervals be-
tween the removal of DOX and injection of ketamine.
Using this approach, we found that rats should be off DOX
(DOX-) for 96 h before ketamine injection to observe RAM
labeling. Worth noting, rats taken off DOX 48 h before
A B C
Figure 2. Low-dose ketamine blunts stress-induced DRN activation. A, Representative photomicrograph showing a 5-HT cell (red
arrow), Fos cell (black arrow), and double-labeled cell expressing 5-HT and Fos (white arrow). B, Total number of Fos cells (left)
and percentage of 5-HT cells also expressing Fos within the rostral, middle, and caudal subregions of the DRN. Tukey’s post hoc
method: p  0.05, p  0.01, p  0.001, p  0.0001. Bars represent group mean  SEM.
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Figure 3. Ketamine-induced RAM labeling of a transcriptionally active neural ensemble that is later activated by uncontrollable stress.
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ketamine showed no change in RAM, relative to saline
treated rats (p  0.65), suggesting that DOX was still
present 48 h after DOX removal. High-dose ketamine, but
not low-dose ketamine or saline, induced robust expres-
sion of RAM in the PL (main effect of drug, F(2,31) 
10.71, p  0.0003). This was not altered by later IS, as
would be expected since the animals were placed back
on DOX 24 h after receiving an injection of ketamine. Post
hoc analysis revealed that rats previously injected with
high-dose ketamine who later received HC showed en-
hanced RAM expression relative to saline injected rats
that later received HC (p  0.039). Similarly, rats previ-
ously injected with high-dose ketamine who later received
IS showed enhanced RAM expression relative to saline
injected rats that later received ID (p  0.023). Next, total
Fos was examined following IS (Fig. 3C,D). As previ-
ously described (Baratta et al., 2009), IS increased the
number of Fos cells in the PL. ANOVA revealed main
effects of stress (F(1,31)  43.69, p  0.0001). Rats previ-
ously injected with saline that received later IS showed
enhanced Fos in the PL, relative to rats previously in-
jected with saline that received HC (p  0.002). Similarly,
rats previously injected with low-dose ketamine that re-
ceived later IS showed enhanced Fos, relative to rats
injected with low-dose ketamine that received HC (p 
0.0004). Finally, the percentage of RAM cells also ex-
pressing Fos was examined to determine whether
ketamine-induced experiential ensembles are recruited at
the time of later IS (Fig. 3C,D). ANOVA yielded main
effects of stress (F(1,31)  8.55, p  0.0064), drug (F(2,31) 
16.31, p  0.0001), and a stress  drug interaction (F(2,31) 
5.031, p  0.013). Strikingly, IS produced a profound
increase in Fos in RAM PL neurons previously acti-
vated by low-dose, but not high-dose, ketamine, com-
pared to rats that received HC and prior saline (p 
0.0001) and IS and prior high-dose ketamine (p  0.001).
Effect of ketamine on activity of the PL-DRN pathway
Previous work from our laboratory has demonstrated
that the PL-DRN pathway is critically involved in the
stress-buffering effects of behavioral control, which
shares several common actions with proactive ketamine.
(Amat et al., 2005, 2014, 2016; Baratta et al., 2009). The
present experiment sought to establish whether prior ket-
amine might activate the PL-DRN pathway in a manner
similar to that described by Baratta et al. (2009) for be-
havioral control. Figure 4A shows a schematic diagram of
the injection procedure. Fos expression was examined in
retrogradely (RB) labeled PL-DRN neurons (Fig. 4B). As
previously described, RB injections in the DRN yielded
expression confined primarily to the deep Layers (V/VI) of
PL and IL, with some expression in the dorsal anterior
cingulate (Gabbott et al., 2005; Baratta et al., 2009; Gon-
çalves et al., 2009; Amat et al., 2016). Worth noting, the
total number of RB PL neurons did not differ between
groups (p  0.496; Fig. 4C, left). To determine whether
ketamine activates the PL, we analyzed the total number
of Fos cells in rats that received ketamine or saline (n 
8 and n  7, respectively; Fig. 4C, middle). A single
injection of ketamine increased the number of Fos cells
in the PL (t(13)  4.145, p  0.001). Next, we assessed
whether ketamine activates the PL-DRN by quantifying
the percentage of DRN-projecting PL neurons expressing
Fos (Fig. 4C, right). Indeed, ketamine produced a robust
increase in activation of the PL-DRN pathway (t(13) 
3.453, p  0.004).
Effect of DREADD-mediated silencing of the PL-DRN
pathway on the stress-buffering effects of ketamine
The goal of the present experiment was to assess
whether chemogenetic inactivation of the PL-DRN path-
way at the time of IS would mitigate the protective effects
of prior ketamine. First, the ability of hM4Di to suppress
ketamine-mediated PL-DRN pathway activation was val-
idated (Fig. 5). Figure 5A depicts the injection procedure
used to target hM4Di to the PL-DRN pathway. Represen-
tative images of hM4Di, Fos, and a hM4Di-positive cells
also expressing Fos are shown in Figure 5B. The total
number of mCherry-expressing cells in the PL was quan-
tified (Fig. 5C, left). As previously shown, DRN-projecting
PL neurons were primarily localized to the deep layers of
PL (Gabbott et al., 2005; Baratta et al., 2009; Gonçalves
et al., 2009). The total number of PL-DRN hM4Di labeled
cells did not differ between the two groups (t(8)  0.22,
p 0.83; Fig. 5C, left). In agreement with the results of the
PL-DRN retrograde tracing experiment, ketamine signifi-
cantly increased the number of Fos cells in the PL (Fig.
5C, middle). Compared to rats injected with vehicle, CNO
significantly reduced ketamine-induced increases in PL
Fos (t(8) 4.337, p 0.003). Next, Fos confined to the
PL-DRN pathway was examined (Fig. 5C, right). Rats
injected with CNO showed significantly lower ketamine-
induced PL-DRN Fos compared to rats injected with
saline (t(8)  4.051, p  0.004).
In a separate cohort of rats expressing PL-DRN hM4Di
or mCherry, ketamine or saline was administered one
continued
A, Schematic timeline of the experimental procedure. Rats were injected with AAV-NLS-RAM-mKate2 (RAM). Nine days later, rats
received a single systemic injection of low-dose ketamine (10 mg/kg, i.p.), high-dose ketamine (40 mg/kg, i.p.), or saline. Seventy-two
hours later, rats were subjected to IS or left undisturbed in their homecage. B, Schematic diagram of a coronal section of rat brain
demonstrating the location of RAM injections into the PL. Viral injection verification was confirmed with eYFP and RAM  Fos were
quantified in the PL subregion denoted with a dashed rectangle. C, Representative images of the PL showing eYFP cells (green),
RAM cells (red), Fos cells (blue), and RAM cells expressing Fos (denoted with yellow arrows in far right panel). Scale bar: 100 m
and applies to all images. D, Enlarged image of the PL showing RAM (denoted with red arrow), Fos (denoted with white arrow), and
a RAM cell expressing Fos (denoted with yellow arrow). Scale bar: 50 m. E, Number of RAM labeled cells (left), Fos cells (middle),
and percentage of double-labeled RAM cells that also express Fos (right) in the PL of rats that received ketamine or saline followed
by later IS or HC treatment. Tukey’s post hoc method: p  0.05, p  0.01, p  0.001 for graph of RAM cells and % RAM
cells expressing Fos. Two-way ANOVA main effect: p  0.001 for graph of Fos. Bars represent group mean  SEM.
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week before IS or HC. Thirty minutes before IS or HC, all
rats were injected with CNO (3.0 mg/kg, i.p.). Therefore,
the experiment was a 2 (stress)  2 (drug)  2 (virus)
factorial design. Twenty-four hours after IS or HC, rats
received JSE testing. Figure 6 shows the time spent
interacting during the JSE test. Three-way ANOVA re-
vealed a main effect of stress (F(1,83) 46.98, p 0.0001),
a stress  drug interaction (F(1,83)  8.81, p  0.004), a
stress virus interaction (F(1,83) 16.31, p 0.0001), and
a stress  drug  virus interaction (F(1,83)  9.97, p 
0.023). Within the HC groups, neither ketamine nor
DREADD-mediated inhibition, or their combination had an
effect on social exploration (p  0.05). Consistent with
work performed in male (Amat et al., 2016) and female rats
(Baratta et al., 2018), IS dramatically reduced social ex-
ploration in rats expressing mCherry, relative to mCherry
rats that received HC (p  0.01). hM4Di had no effect on
IS in rats previously injected with saline. That is, rats
targeted with hM4Di that received saline and IS resem-
bled mCherry-expressing rats that received IS and saline
(p  0.05). In agreement with the results of Figure 1, prior
ketamine, but not saline, administered to rats targeted
with PL-DRN mCherry prevented IS-mediated social ex-
ploration deficits in rats targeted with PL-DRN mCherry (p
 0.01). Strikingly, hM4Di-mediated inhibition of the
PL-DRN pathway at the time of IS eliminated the pro-
tective effects of prior ketamine. Rats that received this
treatment now resembled mCherry rats that received
saline before IS or hM4Di rats that received saline
before IS (p  0.05).
Although not the focus of the present study, there was
significant variability in social exploration for rats that
received HC or IS during each phase of estrus (diestrus,
proestrus, estrus) for the different treatment groups. How-
ever, given the low number of subjects for each stage of
estrous in each experimental group, it is not possible to
know whether stage of estrous is influencing the behav-
ioral outcome measure (Fig. 6).
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Figure 4. Acute ketamine activates the PL-DRN pathway. A, Schematic diagram of the experimental procedure. Rats were injected
with red fluorescent RBs in the DRN. Two weeks later, rats received a single systemic injection of ketamine (10 mg/kg, i.p.) or saline.
Two hours later, rats were killed. RB and Fos expression was assessed in the PL. B, Representative images of the PL showing RB
cells (red), Fos cells (green), and RB Fos (denoted with white arrows in far right panel). Scale bar: 50 m and applies to all images.
C, Number of RB labeled cells (left), Fos cells (middle), and percentage of double-labeled RB-labeled cells that also express Fos
(right) in the PL of rats that received ketamine or saline. Unpaired t test: p  0.01. Bars represent group mean  SEM.
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Discussion
The present study set out to determine whether the
prophylactic effects of ketamine, as well as the neural
mechanisms that mediate its effects, are present in fe-
male rats in a manner similar to that which has previously
been characterized in male rats (Amat et al., 2016). Thus,
we assessed various behavioral and neurochemical end-
points that were examined in previous studies conducted
using male rats, while expanding on earlier efforts by
assessing specific neural ensembles and circuits impli-
cated in the effects of ketamine. The results of the present
experiments provide clear evidence that a single injection
of low-dose, but not high-dose, ketamine delivered one
week before uncontrollable stress (IS) blocks the behav-
ioral effects of IS on JSE measured 24 h later. These
results are in agreement with studies from our laboratory
(Amat et al., 2016) and others (Brachman et al., 2016;
McGowan et al., 2017) demonstrating prophylactic effects
of ketamine in male rats and mice. However, the present
study is the first of its kind to demonstrate ketamine
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Figure 5. hM4Di prevents the effects of prior ketamine on activation of the PL-DRN pathway. A, Schematic diagram of the injection
procedure. Rats were injected with retrogradely transported AAV vectors encoding Cre and eGFP. Five days later, rats were injected
with Cre-dependent AAV vectors encoding hM4Di-mCherry Scale bar: 250 m and applies to both images. B, Representative images
of the PL showing hM4Di-mCherry expression (left), Fos expression (middle), and the colocalization of hM4Di-mCherry and Fos (right).
Scale bar: 50 m. C, Number of hM4Di-mCherry labeled cells (left), Fos cells (middle), and percentage of hM4Di-mCherry
expressing cells that also express Fos (right) in the PL of rats that received ketamine before CNO or vehicle. Unpaired t test: p 
0.01. Bars represent group mean  SEM.
Figure 6. hM4Di-mediated inhibition of the PL-DRN pathway prevents the prophylactic effect of prior ketamine on JSE. Rats
previously injected with hM4Di or mCherry targeted to the PL-DRN pathway received a single injection of saline or ketamine one week
before IS or HC. JSE was assessed 24 h after IS or HC. Tukey’s post hoc method: p  0.01. Bars represent group mean  SEM.
Symbols represent mean social exploration for rats that received HC or IS during diestrus, proestrus, or estrus.
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Table 1.
Figure Data Structure Type of test
ANOVA p values, t
test p values, 95% CI
Fig. 1 Normal distribution Two-way ANOVA Main effect of stress: p  0.0001
Main effect of drug: p  0.0001
Interaction: p  0.0249
Tukey’s multiple comparisons test
Homecage:saline vs homecage:ketamine (10 mg/kg)
Homecage:saline vs homecage:ketamine (40 mg/kg)
Homecage:saline vs stress:saline
Homecage:saline vs stress:ketamine (10 mg/kg)
Homecage:saline vs stress:ketamine (40 mg/kg)
Homecage:ketamine (10 mg/kg) vs Homecage:ketamine (40 mg/kg)
Homecage:ketamine (10 mg/kg) vs stress:saline
Homecage:ketamine (10 mg/kg) vs stress:ketamine (10 mg/kg)
Homecage:ketamine (10 mg/kg) vs stress:ketamine (40 mg/kg)
Homecage:ketamine (40 mg/kg) vs stress:saline
Homecage:ketamine (40 mg/kg) vs stress:ketamine (10 mg/kg)
Homecage:ketamine (40 mg/kg) vs stress:ketamine (40 mg/kg)
Stress:saline vs stress:ketamine (10 mg/kg)
Stress:saline vs stress:ketamine (40 mg/kg)
Stress:ketamine (10 mg/kg) vs stress:ketamine (40 mg/kg)
9	19.55 to 10.49
	10.27 to 20.6
7.037 to 37.08
	17.34 to 12.7
6.635 to 37.5
	5.735 to 25.13
11.57 to 41.61
	12.81 to 17.23
11.16 to 42.03
1.459 to 32.32
	22.92 to 7.942
1.067 to 32.73
	39.4 to 	9.36
	15.42 to 15.44
8.958 to 39.82
Fig. 2 Normal distribution ANOVA
Total 5-HT Rostral Two-way ANOVA Stress: p  0.16
Drug: p  0.47
Interaction: p  0.81
Total 5-HT Middle Two-way ANOVA Stress: p  0.59
Drug: p  0.06
Interaction: p  0.60
Total 5-HT Caudal Two-way ANOVA Stress: p  0.55
Drug: p  0.23
Interaction: p  0.16
Fig. 2, middle ANOVA
Total Fos Rostral Two-way ANOVA Stress: p  0.0004
Drug: p  0.047
Interaction: p  0.055
Tukey’s multiple comparisons test
Saline:HC vs saline:IS
Saline:HC vs ketamine:HC
Saline:HC vs ketamine:IS
Saline:IS vs ketamine:HC
Saline:IS vs ketamine:IS
Ketamine:HC vs ketamine:IS
	25.9 to 	5.303
	10.1 to 10.5
	14.76 to 4.959
5.503 to 26.1
0.8412 to 20.56
	14.96 to 4.759
Total Fos Middle Two-way ANOVA Stress: p  0.0004
Drug: p  0.04
Interaction: p  0.044
Tukey’s multiple comparisons test
Saline:HC vs saline:IS
Saline:HC vs ketamine:HC
Saline:HC vs ketamine:IS
Saline:IS vs ketamine:HC
Saline:IS vs ketamine:IS
Ketamine:HC vs ketamine:IS
	17.4 to 	3.713
	6.544 to 6.744
	9.418 to 3.251
3.526 to 17.78
0.6301 to 14.31
	9.827 to 3.46
Total Fos Caudal Two-way ANOVA Stress: p  0.004
Drug: p  0.62
Interaction: p  0.83
Tukey’s multiple comparisons test
Saline:HC vs saline:IS
Saline:HC vs ketamine:HC
Saline:HC vs ketamine:IS
Saline:IS vs ketamine:HC
Saline:IS vs ketamine:IS
Ketamine:HC vs ketamine:IS
	7.269 to 0.5419
	3.602 to 4.209
	6.341 to 1.069
	0.4295 to 7.763
	3.178 to 4.633
	6.845 to 0.9661
Fig. 2, right Normal distribution
5-HT  Fos Rostral Two-way ANOVA Stress: p  0.0001
Drug: p  0.046
Interaction: p  0.08
Tukey’s multiple comparisons test
Saline:HC vs saline:IS
Saline:HC vs ketamine:HC
Saline:HC vs ketamine:IS
Saline:IS vs ketamine:HC
Saline:IS vs ketamine:IS
Ketamine:HC vs ketamine:IS
	9.626 to 	2.267
	3.43 to 3.929
	5.808 to 1.238
2.516 to 9.876
0.1389 to 7.185
	6.057 to 0.989
(Continued)
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Table 1. Continued
Figure Data Structure Type of test
ANOVA p values, t
test p values, 95% CI
5-HT  Fos Middle Two-way ANOVA Stress: p  0.0001
Drug: p  0.03
Interaction: p  0.03
Tukey’s multiple comparisons test
Saline:HC vs saline:IS
Saline:HC vs ketamine:HC
Saline:HC vs ketamine:IS
Saline:IS vs ketamine:HC
Saline:IS vs ketamine:IS
Ketamine:HC vs ketamine:IS
	7.904 to 	2.494
	2.625 to 2.628
	4.548 to 0.4605
2.382 to 8.019
0.4502 to 5.86
	4.672 to 0.581
5-HT  Fos Caudal Two-way ANOVA Stress: p  0.0001
Drug: p  0.03
Interaction: p  0.03
Tukey’s multiple comparisons test
Saline:HC vs saline:IS
Saline:HC vs ketamine:HC
Saline:HC vs ketamine:IS
Saline:IS vs ketamine:HC
Saline:IS vs ketamine:IS
Ketamine:HC vs ketamine:IS
	4.4 to 	0.994
	1.515 to 1.892
	3.019 to 0.212
1.099 to 4.672
	0.4097 to 2.996
	3.295 to 0.1108
Fig. 3 Normal distribution
Total RAM Two-way ANOVA Stress: p  .99
Drug: p  0.0003
Interaction: p  0.87
Homecage:saline vs Homecage:ketamine (10 mg/kg)
Homecage:saline vs homecage:ketamine (40 mg/kg)
Homecage:saline vs stress:saline
Homecage:saline vs stress:ketamine (10 mg/kg)
Homecage:saline vs stress:ketamine (40 mg/kg)
Homecage:ketamine (10 mg/kg) vs homecage:ketamine (40 mg/kg)
Homecage:ketamine (10 mg/kg) vs stress:saline
Homecage:ketamine (10 mg/kg) vs stress:ketamine (10 mg/kg)
Homecage:ketamine (10 mg/kg) vs stress:ketamine (40 mg/kg)
Homecage:ketamine (40 mg/kg) vs stress:saline
Homecage:ketamine (40 mg/kg) vs stress:ketamine (10 mg/kg)
Homecage:ketamine (40 mg/kg) vs stress:ketamine (40 mg/kg)
Stress:saline vs stress:ketamine (10 mg/kg)
Stress:saline vs stress:ketamine (40 mg/kg)
Stress:ketamine (10 mg/kg) vs stress:ketamine (40 mg/kg)
	46.01 to 13.18
	60.26 to 	1.071
	27.01 to 32.18
	50.1 to 9.096
	57.58 to 	0.5401
	43.85 to 15.35
	10.6 to 48.6
	33.68 to 25.51
	41.16 to 15.88
3.654 to 62.85
	19.43 to 39.76
	26.91 to 30.13
	52.68 to 6.513
	60.16 to 	3.123
	37.08 to 19.96
Total Fos Two-way ANOVA Stress: p  0.0001
Drug: p  0.1326
Interaction: p  0.1498
Homecage:saline vs homecage:ketamine (10 mg/kg)
Homecage:saline vs homecage:ketamine (40 mg/kg)
Homecage:saline vs stress:saline
Homecage:saline vs stress:ketamine (10 mg/kg)
Homecage:saline vs stress:ketamine (40 mg/kg)
Homecage:ketamine (10 mg/kg) vs homecage:ketamine (40 mg/kg)
Homecage:ketamine (10 mg/kg) vs stress:saline
Homecage:ketamine (10 mg/kg) vs stress:ketamine (10 mg/kg)
Homecage:ketamine (10 mg/kg) vs stress:ketamine (40 mg/kg)
Homecage:ketamine (40 mg/kg) vs stress:saline
Homecage:ketamine (40 mg/kg) vs stress:ketamine (10 mg/kg)
Homecage:ketamine (40 mg/kg) vs stress:ketamine (40 mg/kg)
Stress:saline vs stress:ketamine (10 mg/kg)
Stress:saline vs stress:ketamine (40 mg/kg)
Stress:ketamine (10 mg/kg) vs stress:ketamine (40 mg/kg)
	27.09 to 12.92
	34.42 to 5.587
	48.67 to 	8.663
	59 to 	19
	47.66 to 	9.105
	27.34 to 12.67
	41.59 to 	1.579
	51.92 to 	11.91
	40.57 to 	2.021
	34.25 to 5.754
	44.59 to 	4.579
	33.24 to 5.312
	30.34 to 9.671
	18.99 to 19.56
	8.657 to 29.9
% RAM  Fos Two-way ANOVA Stress: p  0.0064
Drug: p  0.0001
Interaction: p  0.0128
Homecage:saline vs homecage:ketamine (10 mg/kg)
Homecage:saline vs homecage:ketamine (40 mg/kg)
Homecage:saline vs stress:saline
Homecage:saline vs stress:ketamine (10 mg/kg)
Homecage:saline vs stress:ketamine (40 mg/kg)
Homecage:ketamine (10 mg/kg) vs homecage:ketamine (40 mg/kg)
Homecage:ketamine (10 mg/kg) vs stress:saline
Homecage:ketamine (10 mg/kg) vs stress:ketamine (10 mg/kg)
Homecage:ketamine (10 mg/kg) vs stress:ketamine (40 mg/kg)
Homecage:ketamine (40 mg/kg) vs stress:saline
Homecage:ketamine (40 mg/kg) vs stress:ketamine (10 mg/kg)
Homecage:ketamine (40 mg/kg) vs stress:ketamine (40 mg/kg)
	21.56 to 5.718
	16.43 to 10.84
	13.64 to 13.64
	40.35 to 	13.07
	19.63 to 6.654
	8.516 to 18.76
	5.718 to 21.56
	32.43 to 	5.156
	11.71 to 14.57
	10.84 to 16.43
	37.55 to 	10.28
	16.83 to 9.452
(Continued)
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prophylaxis in female rats, and suggests that the prophy-
lactic effects of ketamine on later stress outcomes are
generalizable to both sexes. This was especially an issue
as behavioral control, which has similarities to the effects
of ketamine, is not protective in female rats (Baratta et al.,
2018), at least under circumstances identical to those
used in males (see below).
A significant body of research, primarily derived in male
rodents, indicates that behavioral changes produced by
IS, including reduced JSE, are mediated by activation of
the middle and caudal 5-HT DRN and subsequent release
of 5-HT into brain areas such as the BLA (Takase et al.,
2004; Amat et al., 2008; Christianson et al., 2010; Dolzani
et al., 2016). This intense activation of the DRN is both
necessary (Maier et al., 1993, 1994, 1995) and sufficient
(Maier et al., 1995) for behavioral changes associated with
IS. Thus, we sought to determine whether ketamine ad-
ministered before IS would mitigate DRN activation typi-
cally associated with exposure to IS. Indeed, a single
injection of ketamine one week before IS significantly
reduced stress-induced activation of the rostral and mid-
dle DRN. Although not the focus of the present experi-
ments, it is possible that differences in DRN subregion
activation between the female and male studies are due to
sex-specific differences in DRN anatomy. While females
are reported to have higher basal and stress-induced
levels of 5-HT (Domínguez et al., 2003; Mitsushima et al.,
2006; Staiti et al., 2011), sex differences in DRN anatomy
have received little study. Indeed, one limitation of the
present experiments is the use of Fos as the sole marker
for DRN 5-HT activation. Indeed, Fos is an immediate
early gene that is used to detect recently activated neu-
rons (Sheng et al., 1990) yet unlike in vivo microdialysis
where extracellular 5-HT can be directly measured, Fos
serves as a proxy for DRN 5-HT activation. Even so, the
results of the double label IHC experiments strongly sug-
gest that prior ketamine reduces DRN 5-HT activation at
the time of stress.
As noted, here we have shown that ketamine blunts
both the neurochemical and behavioral consequences of
IS when administered one week before the stressor. To
date, no other manipulations have demonstrated an ability
to produce these effects in female rats. An extensive body
of work has revealed that behavioral control over a stres-
sor prevents the neurochemical and behavioral effects of
the stressor in male rats (for review, see Maier et al.,
2015). Surprisingly, the protective effects of behavioral
control are absent in female rats (Baratta et al., in press).
The stress-buffering effects of behavioral control ob-
served in male rats have been studied in a paradigm in
which rats are provided a controlling response (turning a
wheel) over termination of tailshocks (escapable tailshock;
ES). A separate group of rats receives an identical series
of yoked tailshocks, however, they are unable to control
any aspect of the tailshock (IS). Behavioral control blunts
DRN activation during the controllable stressor and pre-
vents stress-induced behavioral effects typically mea-
sured 24 h later. As previously described, behavioral
effects of IS are the result of DRN activation and release
of 5-HT into projection regions that are proximal media-
tors of behaviors associated with the stressor (Grahn
et al., 2000; Takase et al., 2004; Amat et al., 2008; Chris-
tianson et al., 2010; Dolzani et al., 2016). In male rats,
behavioral control activates neurons in the deep Layers
(V/VI) of the PL of the mPFC that preferentially synapse on
GABAergic interneurons within the DRN (Hajós et al., 1998;
Jankowski and Sesack, 2004; Gonçalves et al., 2009). Thus,
the net effect of activation of the PL-DRN pathway is re-
duced DRN 5-HT release and blockade of behavioral effects
associated with stressor exposure (Amat et al., 2005). Addi-
tionally, experience with ES prevents DRN activation and the
behavioral effects of an exposure IS or another stressor such
Table 1. Continued
Figure Data Structure Type of test
ANOVA p values, t
test p values, 95% CI
Stress:saline vs stress:ketamine (10 mg/kg)
Stress:saline vs stress:ketamine (40 mg/kg)
Stress:ketamine (10 mg/kg) vs stress:ketamine (40 mg/kg)
	40.35 to 	13.07
	19.63 to 6.654
7.084 to 33.37
Fig. 4
Total RB
Normal distribution Independent samples t test
T,df
p  0.49
t  0.70; df  13
Fig. 4
Total Fos
Normal distribution Independent samples t test
T,df
p  0.0012
t  4.145; df  13
Fig. 4C
% Double Label
Normal distribution Independent samples t test
T,df
p  0.0043
t  3.453; df  13
Fig. 5 Normal distribution Independent samples t test
T,df
Total hM4Di p  0.83
t  0.21; df  8
Total Fos p  0.0025
t  0.4.34; df  8
hM4Di  Fos p  0.0037
t  4.05; df  8
Fig. 6 Normal distribution Three-way ANOVA p value, power
Drug
Stress
Virus
DrugStress
DrugVirus
StressVirus
DrugStressVirus
0.053, 0.47
0.0001, 1.0
0.085, 0.39
0.004, 0.851
0.18, 0.252
0.0001, 0.989
0.023, 0.59
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as social defeat one week later (Amat et al., 2006; Amat
et al., 2010). Surprisingly, behavioral control fails to activate
the PL-DRN pathway in females, and so DRN-mediated
behavioral outcomes are not prevented (Baratta et al., 2018).
In male rats, the protection afforded by ES against the
impact of later uncontrollable stressors is caused by a
state change in DRN-projecting PL neurons produced by
the initial ES, so that the later experience with IS now
activates the PL-DRN pathway (Baratta et al., 2009). Re-
cently, it has also been shown that behavioral control
induces plasticity within deep Layer (V/VI) PL neurons that
are anatomically situated to prevent DRN activation
(Hajós et al., 1998; Varela et al., 2012; Amat et al., 2014).
Moreover, blockade of plasticity within the PL with protein
synthesis inhibitors, APV, and ERK inhibitors before ES all
prevent ES from protecting against the behavioral effects
of later IS (Amat et al., 2006; Amat et al., 2014; Christian-
son et al., 2014). It should be noted that the effects of
low-dose ketamine are distinct from those of other NMDA
receptor antagonists, such as APV (for review, see Abdal-
lah et al., 2015).
Similar to the effects of behavioral control in male rats,
a single subanesthetic injection of ketamine enhances
synaptic plasticity in PL Layer V (Li et al., 2010) and both
prevents (Li et al., 2010; Amat et al., 2016; Brachman
et al., 2016; McGowan et al., 2017) and reverses (Li et al.,
2011) the effects of stressor exposure. Furthermore, ket-
amine delivered to male rats induces PL Fos activation
(Fuchikami et al., 2015; Amat et al., 2016) and alters
PL-DRN neurons so that an experience with IS now acti-
vates this pathway (Amat et al., 2016). Given the similar-
ities between the effects of behavioral control and
ketamine on later outcomes of IS, we sought to determine
whether ketamine alters PL activity in a manner whereby
a later experience with IS activates the ensemble of PL
neurons initially activated by ketamine. Using RAM, we
revealed that low-dose, but not high-dose, ketamine ac-
tivates ensembles of neurons that are later brought online
by IS. This is the strongest evidence to date to suggest
that alterations in specific assemblies of PL neurons are
involved in the prophylactic effects of ketamine. Others
have shown that positive experiences activate neural en-
sembles in the dentate gyrus and reactivation of these
ensembles is sufficient to reverse depression-like behav-
iors (Ramirez et al., 2015). Future studies should imple-
ment similar methodologies to demonstrate necessity of
experiential ensembles in the prophylactic effects of prior
ketamine.
Given the effect of ketamine on stress-induced DRN
activation and PL activity at the time of drug injection and
later IS, we sought to determine whether an acute injec-
tion of ketamine activates the PL-DRN pathway and
whether activation of this pathway at the time of later IS is
necessary for the protective effects of the drug. The re-
sults of the retrograde tracing study revealed that an
acute injection of ketamine activates the PL-DRN path-
way. Using a dual virus intersectional genetic strategy, we
found that DREADD-mediated inhibition of the PL-DRN
pathway at the time of IS prevents the protective effects
of ketamine given one week earlier. Others have identified
mPFC-hippocampus circuits involved in the acute effects
of ketamine given shortly before behavioral testing (Car-
reno et al., 2016), however this is the first study to reveal
a precise neural circuit that mediates the prophylactic
effects of ketamine in females. It should be noted that
although nonspecific neural and behavioral effects related
to CNO metabolism in DREADD experiments have been
noted (Gomez et al., 2017), all rats in the present experi-
ment received CNO, and so it is clear that a CNO metab-
olite is not mediating the observed effects on behavior.
Taken together, the present experiments indicate that
ketamine exerts long-lasting prophylactic effects against
the deleterious outcomes of stress in female rats. The
effects of ketamine persist much longer than the plasma
half-life of 2 h in rats (Williams et al., 2004), and so the
observed effects cannot be attributed to acute drug ef-
fects at the time of behavioral testing. The pattern of the
data suggests that the effects of ketamine mirror the
long-lasting prophylaxis that occurs in male rats provided
with behavioral control. This data suggests that while
behavioral control fails to protect female rats, the neces-
sary resilience circuitry does exist and is engaged by
ketamine. Therefore, ketamine may prove effective as a
therapeutic strategy for female clinical populations likely
to experience high levels of stress or trauma.
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